Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Osteoporosis
•
Bisphosphonate
Do you use bisphosphonates in combination with SERMs in female patients with progressive decline in bone density despite being on a SERM for post-menopausal symptoms other than osteoporosis?
Related Questions
How would you approach treatment of glucocorticoid induced osteoporosis in a patient 10 years post renal transplant, egfr > or =35, on chronic prednisone therapy who has completed 10 years of bisphosphonate therapy and whose DEXA continues to be T-score <~2.5?
For postmenopausal osteoporosis, would you give denosumab after a course of teriparatide and romosozumab to women who had an atypical femoral fracture while on bisphosphonate therapy a few years earlier?
In a patient with history of atypical femoral fracture while on denosumab how do you sequence further treatment options?
What do you consider as absolute and relative contraindications for the use of romosozumab?
Would you transition from denosumab to anabolic agents in patients who are in urgent need for extensive dental work?
How do you approach long term management of glucocorticoid-induced osteoporosis in patients who develop osteonecrosis of the jaw on antiresorptive agent?
What is your approach to management of severe osteoporosis in patients with advanced kidney disease?
When considering pharmacologic treatments recommended by the 2022 glucocorticoid induced osteoporosis guidelines, do you use NNT/NNH to select between each treatment option by risk categories (e.g., moderate, high, very high)?
What is your approach to managing osteoporosis in patients with end stage kidney disease?
Can raloxifene be combined with stronger osteoporosis agents in patients who are on raloxifene for a breast cancer diagnosis?
